Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$24.30 +2.7%	$19.94	$13.36 ▼ $32.27	$782.17M	1.43	370,216 shs	366,858 shs
IBRX ImmunityBio	$2.31 +3.1%	$2.66	$1.83 ▼ $7.48	$2.18B	0.12	9.55 million shs	9.52 million shs
KNSA Kiniksa Pharmaceuticals International	$33.75 +0.5%	$29.78	$17.82 ▼ $34.55	$2.50B	0.14	705,288 shs	356,168 shs
OGN Organon & Co.	$9.42 +1.5%	$9.68	$8.01 ▼ $23.10	$2.45B	0.6	4.78 million shs	3.55 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	+17.16%	+11.52%	+31.92%	-14.83%
IBRX ImmunityBio	0.00%	-9.41%	-23.26%	-8.70%	-47.50%
KNSA Kiniksa Pharmaceuticals International	0.00%	+1.11%	+25.46%	+25.51%	+27.70%
OGN Organon & Co.	0.00%	-0.11%	-6.42%	+8.40%	-55.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNTH Dianthus Therapeutics	1.0682 of 5 stars	3.5	0.0	0.0	0.0	1.0	0.8	0.0
IBRX ImmunityBio	2.5144 of 5 stars	3.6	1.0	0.0	0.0	3.2	1.7	0.6
KNSA Kiniksa Pharmaceuticals International	2.6925 of 5 stars	2.5	3.0	0.0	0.0	3.4	3.3	0.6
OGN Organon & Co.	4.7545 of 5 stars	3.3	2.0	1.7	3.7	3.6	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	122.22% Upside
IBRX ImmunityBio	3.20	Buy	$10.75	365.37% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	21.98% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	91.08% Upside

Current Analyst Ratings Breakdown

Latest DNTH, OGN, KNSA, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/14/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/5/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/25/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$6.24M	125.36	N/A	N/A	$9.42 per share	2.58
IBRX ImmunityBio	$14.74M	148.14	N/A	N/A	($0.60) per share	-3.85
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.91	N/A	N/A	$6.68 per share	5.05
OGN Organon & Co.	$6.40B	0.38	$4.93 per share	1.91	$2.82 per share	3.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)
IBRX ImmunityBio	-$413.56M	-$0.48	N/A	N/A	N/A	-648.57%	N/A	-113.86%	11/11/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	843.96	135.00	N/A	0.90%	1.05%	0.80%	11/4/2025 (Estimated)
OGN Organon & Co.	$864M	$2.69	3.50	2.52	0.98	11.15%	163.88%	6.99%	10/30/2025 (Estimated)

Latest DNTH, OGN, KNSA, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million
8/5/2025	Q2 2025	IBRX ImmunityBio	-$0.10	-$0.10	N/A	-$0.10	$21.95 million	$26.43 million
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.97%	N/A

Latest DNTH, OGN, KNSA, and IBRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	13.12	13.12
IBRX ImmunityBio	N/A	4.11	3.98
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.16
OGN Organon & Co.	11.98	1.65	1.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
IBRX ImmunityBio	8.58%
KNSA Kiniksa Pharmaceuticals International	53.95%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	8.15%
IBRX ImmunityBio	76.79%
KNSA Kiniksa Pharmaceuticals International	53.48%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	80	32.19 million	29.57 million	Optionable
IBRX ImmunityBio	590	945.26 million	219.39 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	74.11 million	34.48 million	Optionable
OGN Organon & Co.	4,000	259.97 million	254.87 million	Not Optionable

DNTH, OGN, KNSA, and IBRX Headlines

Recent News About These Companies

Algert Global LLC Acquires New Stake in Organon & Co. $OGN

August 23 at 5:04 AM | marketbeat.com

Invesco Ltd. Has $28.85 Million Position in Organon & Co. $OGN

August 22 at 3:38 AM | marketbeat.com

Organon & Co. (NYSE:OGN) Shares Sold by Brandywine Global Investment Management LLC

August 18, 2025 | marketbeat.com

Russell Investments Group Ltd. Sells 128,059 Shares of Organon & Co. (NYSE:OGN)

August 18, 2025 | marketbeat.com

Vanguard Group Inc. Sells 699,976 Shares of Organon & Co. (NYSE:OGN)

August 17, 2025 | marketbeat.com

Organon & Co. (NYSE:OGN) Shares Purchased by KLCM Advisors Inc.

August 16, 2025 | marketbeat.com

There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings

August 15, 2025 | finance.yahoo.com

LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN)

August 15, 2025 | marketbeat.com

Public Sector Pension Investment Board Has $12.16 Million Position in Organon & Co. (NYSE:OGN)

August 14, 2025 | marketbeat.com

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

August 13, 2025 | prnewswire.com

Organon: Valuation Discount Offset By Structural Headwinds

August 12, 2025 | seekingalpha.com

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

August 12, 2025 | zacks.com

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend

August 11, 2025 | finance.yahoo.com

OGN vs. HQY: Which Stock Is the Better Value Option?

August 8, 2025 | zacks.com

Organon & Co. (NYSE:OGN) Given Average Recommendation of "Moderate Buy" by Brokerages

August 8, 2025 | marketbeat.com

Organon & Co. to Issue Quarterly Dividend of $0.02 (NYSE:OGN)

August 7, 2025 | marketbeat.com

Organon & Co. (OGN) Reports Q2 2025 Results

August 7, 2025 | insidermonkey.com

Organon & Co. Earnings Call: Resilience Amid Challenges

August 7, 2025 | theglobeandmail.com

Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

August 7, 2025 | finance.yahoo.com

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

August 6, 2025 | seekingalpha.com

Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH, OGN, KNSA, and IBRX Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$24.30 +0.65 (+2.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$24.33 +0.03 (+0.12%)

As of 08/22/2025 06:38 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

ImmunityBio NASDAQ:IBRX

$2.31 +0.07 (+3.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.00 (+0.22%)

As of 08/22/2025 07:57 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$33.75 +0.17 (+0.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$33.44 -0.31 (-0.92%)

As of 08/22/2025 07:05 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Organon & Co. NYSE:OGN

$9.42 +0.14 (+1.51%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$9.44 +0.02 (+0.16%)

As of 08/22/2025 05:06 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time